SynthesisFrontiers in pharmacology2026
Pharmacological effects and mechanisms of curcumin in animal models of Parkinson's disease: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Curcumin has been demonstrated to possess promising neuroprotective potential in Parkinson's disease; however, its overall effects remain inconclusive, and its multiple mechanisms of action have not been systematically summarized. Objective: This systematic review and meta-analysis aimed to evaluate the pharmacological effects of curcumin in animal models of Parkinson's disease and to investigate its potential mechanisms involving antioxidant, anti-inflammatory, and neuroprotective effects, thereby providing a theoretical basis for its potential clinical application in Parkinson's disease. Methods: A comprehensive search of four databases (EMBASE, PubMed, Web of Science, and the Cochrane Library) up to August 2025 identified 31 eligible studies involving a total of 552 animals. Methodological quality was assessed using the SYRCLE risk of bias tool. Standardized mean differences (SMDs) were calculated to evaluate the effects of curcumin on motor function, neurochemistry, inflammation, and oxidative stress in animal models of Parkinson's disease. Results: The results demonstrated that curcumin intervention improved motor function in animal models of Parkinson's disease, as evidenced by increased locomotor distance in the open field test (SMD = 1.25) and elevated mean velocity (SMD = 1.42), prolonged latency to fall in the rotarod test (SMD = 2.49), shortened descent time in the pole test (SMD = -1.16), and reduced traversal time on the balance beam (SMD = -2.27). Curcumin exhibited neuroprotective effects through increasing the number of tyrosine hydroxylase-positive cells (SMD = 2.12), maintaining dopamine levels (SMD = 4.11), and elevating 3,4-dihydroxyphenylacetic acid concentrations (SMD = 3.15). Regarding anti-inflammatory effects, curcumin significantly reduced multiple inflammatory markers, including interleukin-6 (SMD = -4.73), interleukin-1β (SMD = -3.30), tumor necrosis factor-α (SMD = -3.19), and nitric oxide (SMD = -4.91). With respect to antioxidant activity, curcumin significantly reduced malondialdehyde levels (SMD = -4.69) while increasing the activities of superoxide dismutase (SMD = 3.90), glutathione (SMD = 2.08), and catalase (SMD = 2.00). Conclusion: Curcumin demonstrates significant neuroprotective effects in Parkinson's disease animal models, improving motor deficits and neuronal integrity likely through multi-target mechanisms involving anti-inflammatory and antioxidant pathways. Systematic Review Register: https://www.crd.york.ac.uk/PROSPERO/view/CRD420251131257, identifier CRD420251131257.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.